Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Department of Ophthalmology, Etimesgut Military Hospital, Ankara, Turkey. s.uzun84@gmail.com.|Etimesgut Asker Hastanesi Goz Hastaliklari Servisi, 06790, Etimesgut-Ankara, Turkey. s.uzun84@gmail.com.
Salih
S
Uzun
Department of Ophthalmology, Eskisehir Military Hospital, Eskisehir, Turkey.
Emre
E
Pehlivan
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D002829:Choroid / Q000000981:diagnostic imaging*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab